---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-009060"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:38:56.437416+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma Q4 product sales $21.3M (+83% YoY); guides FY26 rev >$110M, 30%+ EBITDA margin

## Summary
- Q4 product sales $21.3M (+83% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.19; Adj. EBITDA $6.2M
- Launched DESMODA (first FDA-approved desmopressin oral solution) on March 9, 2026
- Acquired U.S. rights to Orphan Drug HEMANGEOL; relaunch May 1, 2026; accretive to 2026 earnings
- FY 2026 guidance: revenue >$110M, Adj. EBITDA margin >30%
- Cash $25.9M at Dec 31, 2025; net income $1.5M vs loss $5.4M prior year

## SEC filing metadata
- accession: 0001437749-26-009060
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009060/0001437749-26-009060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926009060/eton20251117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-009060
- JSON: https://secwatch.observer/filing/0001437749-26-009060.json
- Plain text: https://secwatch.observer/filing/0001437749-26-009060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.